• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Role of VEGF165b in neovascular vitreoretinal diseases and development of treatments for it

Research Project

Project/Area Number 24592668
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Ophthalmology
Research InstitutionShiga University of Medical Science

Principal Investigator

OHJI Masahito  滋賀医科大学, 医学部, 教授 (90252650)

Co-Investigator(Kenkyū-buntansha) KAKINOKI Masashi  滋賀医科大学, 医学部, 助教 (80531516)
Project Period (FY) 2012-04-01 – 2015-03-31
Project Status Completed (Fiscal Year 2014)
Budget Amount *help
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
KeywordsVEGF / VEGF165b / 抗VEGF薬 / 眼内薬物動態 / VEGFa65b / アイソフォーム / ペガプタニブ / カニクイザル
Outline of Final Research Achievements

VEGF concentration increased after intravitreal injection of pegaptanib sodium into macaque eyes and there was no difference in the increase among the isoforms. Pegaptanib increased VEGF165 production by cultured ARPE65 cells while it did not increase VEGF165b production.
In monkey experiments, the half-lives of intravitreally injected ranibizumab (IVR) and aflibercept (IVA) in the aqueous humor were similar and they were shorter in vitrectomized eyes. IVA suppressed VEGF level in the injected eyes for longer period compared with IVR. IVA also, but not IVR suppressed VEGF level in untreated fellow eye for a short period. The pharmacokinetics of anti-VEGF drugs and its effect may be different among drugs. It is also different between in vitrectomized eyes and non-vitrectomized eyes. In AMD patients, IVA completely suppress aqueous VEGF for 2 months while IVR partially suppress VEGF at 2 month after injection. IVA suppressed serum and plasma VEGF while IVR did not.

Report

(4 results)
  • 2014 Annual Research Report   Final Research Report ( PDF )
  • 2013 Research-status Report
  • 2012 Research-status Report
  • Research Products

    (8 results)

All 2014 2013

All Journal Article (3 results) (of which Peer Reviewed: 3 results,  Acknowledgement Compliant: 1 results) Presentation (5 results) (of which Invited: 2 results)

  • [Journal Article] Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.2014

    • Author(s)
      Wang X, Sawada T, Sawada O, Saishin Y, Liu P, Ohji M
    • Journal Title

      American journal of ophthalmology

      Volume: 158 Issue: 4 Pages: 738-744

    • DOI

      10.1016/j.ajo.2014.06.009

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration2014

    • Author(s)
      Wang X, Sawada O, Miyake T, Kakinoki M, Sawada T, Miyake T, Kawamura H, Saishin Y, Liu P, Ohji M
    • Journal Title

      Graefes Arch Clin Exp Ophthalmol

      Volume: 252 Issue: 7 Pages: 1033-1039

    • DOI

      10.1007/s00417-013-2505-2

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed / Acknowledgement Compliant
  • [Journal Article] Correlation between vascular endothelial graowth factor and nonperfused areas in macular edema secondary to branchretinal vein occlusion.2013

    • Author(s)
      Fujikawa M, Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Ohji M
    • Journal Title

      Clin Ophthalmol

      Volume: 7 Pages: 1497-1501

    • DOI

      10.2147/opth.s46817

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Presentation] Optimal treatments for age-related macular degeneration2014

    • Author(s)
      Ohji M
    • Organizer
      19th Congerss of Chinese Ophthalmological Society
    • Place of Presentation
      Xi'an, People's Republic of China
    • Year and Date
      2014-09-18 – 2014-09-19
    • Related Report
      2014 Annual Research Report
    • Invited
  • [Presentation] Serum vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration2014

    • Author(s)
      Ohji M
    • Organizer
      Club Jules Gonin
    • Place of Presentation
      Zurich, Swiss Confederation
    • Year and Date
      2014-09-03 – 2014-09-06
    • Related Report
      2014 Annual Research Report
  • [Presentation] Age-related macular degeneration: Optimal regimen of anti-VEGF treatments2014

    • Author(s)
      Ohji M
    • Organizer
      International Symposium of Vitreoretinal Diseases
    • Place of Presentation
      Taipei, Taiwan
    • Year and Date
      2014-08-31
    • Related Report
      2014 Annual Research Report
    • Invited
  • [Presentation] Serum and aqueous vascular endothelial growth factor concentration of patients with age-related macular degeneration after intravitreal injection of aflibercept2014

    • Author(s)
      Xiying Wang, Tomoko Sawada, Osamu Sawada, Yoshitsugu Saishin, Masahito Ohji
    • Organizer
      ARVO
    • Place of Presentation
      Orlando, United States of America
    • Year and Date
      2014-05-03 – 2014-05-07
    • Related Report
      2014 Annual Research Report
  • [Presentation] Ranibizumab Concentrations after Monthly and Bimonthly Intravitreal Injections of Ranibizumab for Age-Related Macular Degeneration2013

    • Author(s)
      Xiying Wang, Tomoko Sawada, Masashi Kakinoki, Taichiro Miyake, Osamu Sawada, Hajime Kawamura, Yoshitsugu Saishin, Ping Liu, Masahito Ohji
    • Organizer
      ARVO
    • Place of Presentation
      Seattle, USA
    • Related Report
      2013 Research-status Report

URL: 

Published: 2013-05-31   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi